15 April 2025 ORYZON announces first patient dosed in NCI-sponsored Phase I/II clinical trial of iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer
1-3 April 2025 Van Lanschot Kempen Life Sciences Conference Van Lanschot Kempen Amsterdam Netherlands
5 March 2025 Oryzon announces publication of study on Phelan-McDermid Syndrome (PMS) patients, a form of autism, paving the way for a novel personalized medicine approach with vafidemstat
3 March 2025 Oryzon defines Phase III Trial endpoints for Agitation and Aggression in BPD with input from new Clinical Advisory Board
28 February 2025 ORYZON announces the voting results of February 2025 Extraordinary General Shareholders' Meeting